Hjem › Rabdomiosarkom › California
Kliniske studier for Rabdomiosarkom i California
7 studier for Rabdomiosarkom søker deltakere på steder i California.
Offisiell studietekst (engelsk)
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- UCSF Benioff Children's Hospital, San Francisco
RekruttererFase 1
24 Months – 18 Years · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
RekruttererFase 1/2
Opp til 30 år · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- Cedars-Sinai Medical Center, Los Angeles
- og 4 flere
RekruttererFase 3
Opp til 50 år · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07466316Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
RekruttererFase 1/2
Alder 1 til 30 · Alle kjønn · Oppdatert 22. jul. 2026 · NCT06721689Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
- Stanford University, Palo Alto
RekruttererFase 2
Opp til 22 år · Alle kjønn · Oppdatert 15. jun. 2026 · NCT06023641Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
RekruttererFase 1/2
12 Months – 30 Years · Alle kjønn · Oppdatert 19. mai 2026 · NCT04901702Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.